T Cells Engineered with Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice

Molecular Therapy

Volumn 23, Issue 10, 2015, Pages 1600-1610

  VanSeggelen, Heather ^a   Hammill, Joanne A ^a   Dvorkin Gheva, Anna ^a   Tantalo, Daniela G M ^a   Kwiecien, Jacek M ^b,c   Denisova, Galina F ^a   Rabinovich, Brian ^d   Wan, Yonghong ^a   Bramson, Jonathan L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d Lion Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; HYBRID PROTEIN; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; CYTOKINE; HCST PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CONTROLLED STUDY; FEMALE; IMMUNOPATHOLOGY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; STRAIN DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL MEMBRANE; CYTOTOXICITY; DISEASE MODEL; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; PNEUMONIA; RETROVIRIDAE; TRANSPLANTATION CONDITIONING; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CYCLOPHOSPHAMIDE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; IMMUNOTHERAPY, ADOPTIVE; LIGANDS; MICE; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PNEUMONIA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING;

EID: 84943579933     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.119     Document Type: Article

References (55)

1. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
2. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
3. Maus, MV, Grupp, SA, Porter, DL and June, CH (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625-2635.
4. Aranda, F, Vacchelli, E, Obrist, F, Eggermont, A, Galon, J, Herve Fridman, W et al. (2014). Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 3: e28344.
5. Spear, P, Barber, A, Rynda-Apple, A and Sentman, CL (2013). NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 91: 435-440.
6. Nausch, N and Cerwenka, A (2008). NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
7. Barber, A, Meehan, KR and Sentman, CL (2011). Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther 18: 509-516.
8. Leung, WH, Vong, QP, Lin, W, Janke, L, Chen, T and Leung, W (2013). Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR? activation. J Exp Med 210: 2675-2692.
9. Zhang, T, Lemoi, BA and Sentman, CL (2005). Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
10. Zhang, T and Sentman, CL (2013). Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 190: 2455-2463.
11. Barber, A, Zhang, T, DeMars, LR, Conejo-Garcia, J, Roby, KF and Sentman, CL (2007). Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 67: 5003-5008.
12. Jamieson, AM, Diefenbach, A, McMahon, CW, Xiong, N, Carlyle, JR and Raulet, DH (2002). The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
13. Long, EO (2002). Versatile signaling through NKG2D. Nat Immunol 3: 1119-1120.
14. Groh, V, Rhinehart, R, Randolph-Habecker, J, Topp, MS, Riddell, SR and Spies, T (2001). Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2: 255-260.
15. Verneris, MR, Karimi, M, Karami, M, Baker, J, Jayaswal, A and Negrin, RS (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072.
16. Upshaw, JL and Leibson, PJ (2006). NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 18: 167-175.
17. Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
18. Song, DG, Ye, Q, Carpenito, C, Poussin, M, Wang, LP, Ji, C et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71: 4617-4627.
19. Milone, MC, Fish, JD, Carpenito, C, Carroll, RG, Binder, GK, Teachey, D et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464.
20. Till, BG, Jensen, MC, Wang, J, Qian, X, Gopal, AK, Maloney, DG et al. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.
21. Wu, J, Song, Y, Bakker, AB, Bauer, S, Spies, T, Lanier, LL et al. (1999). An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
22. Brentjens, RJ, Riviere, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
23. Cheadle, EJ, Gilham, DE and Hawkins, RE (2008). The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol 142: 65-68.
24. Dotti, G, Gottschalk, S, Savoldo, B and Brenner, MK (2014). Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257: 107-126.
25. Champsaur, M and Lanier, LL (2010). Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285.
26. Eagle, RA, Jafferji, I and Barrow, AD (2009). Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev 5: 22-34.
27. Borchers, MT, Harris, NL, Wesselkamper, SC, Vitucci, M and Cosman, D (2006). NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 291: L222-L231.
28. Kraetzel, K, Stoelcker, B, Eissner, G, Multhoff, G, Pfeifer, M, Holler, E et al. (2008). NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells. Eur Respir J 32: 563-570.
29. Gonzalez, S, Lopez-Soto, A, Suarez-Alvarez, B, Lopez-Vazquez, A and Lopez-Larrea, C (2008). NKG2D ligands: key targets of the immune response. Trends Immunol 29: 397-403.
30. Ogasawara, K, Benjamin, J, Takaki, R, Phillips, JH and Lanier, LL (2005). Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 6: 938-945.
31. Zhang, H, Hardamon, C, Sagoe, B, Ngolab, J and Bui, JD (2011). Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression. Mol Immunol 48: 539-545.
32. Malarkannan, S, Shih, PP, Eden, PA, Horng, T, Zuberi, AR, Christianson, G et al. (1998). The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 161: 3501-3509.
33. Takada, A, Yoshida, S, Kajikawa, M, Miyatake, Y, Tomaru, U, Sakai, M et al. (2008). Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. J Immunol 180: 1678-1685.
34. Cerwenka, A and Lanier, LL (2003). NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61: 335-343.
35. Ericsson, AC, Davis, JW, Spollen, W, Bivens, N, Givan, S, Hagan, CE et al. (2015). Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PLoS One 10: e0116704.
36. Ichinohe, T, Pang, IK, Kumamoto, Y, Peaper, DR, Ho, JH, Murray, TS et al. (2011). Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 108: 5354-5359.
37. Viaud, S, Saccheri, F, Mignot, G, Yamazaki, T, Daillere, R, Hannani, D et al. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342: 971-976.
38. Moretta, L and Moretta, A (2004). Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259.
39. Long, EO, Kim, HS, Liu, D, Peterson, ME and Rajagopalan, S (2013). Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31: 227-258.
40. Chang, YH, Connolly, J, Shimasaki, N, Mimura, K, Kono, K and Campana, D (2013). A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73: 1777-1786.
41. Zhang, T and Sentman, CL (2011). Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 71: 2066-2076.
42. Lehner, M, Gotz, G, Proff, J, Schaft, N, Dorrie, J, Full, F et al. (2012). Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 7: e31210.
43. Song, DG, Ye, Q, Santoro, S, Fang, C, Best, A and Powell, DJ Jr (2013). Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther 24: 295-305.
44. Stauss, HJ and Morris, EC (2013). Immunotherapy with genemodified T cells: limiting side effects provides new challenges. Gene Ther 20: 1029-1032.
45. Rabinovich, BA, Ye, Y, Etto, T, Chen, JQ, Levitsky, HI, Overwijk, WW et al. (2008). Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 105: 14342-14346.
46. Szymczak, AL, Workman, CJ, Wang, Y, Vignali, KM, Dilioglou, S, Vanin, EF et al. (2004). Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
47. Haynes, NM, Trapani, JA, Teng, MW, Jackson, JT, Cerruti, L, Jane, SM et al. (2002). Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163.
48. Morita, S, Kojima, T and Kitamura, T (2000). Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7: 1063-1066.
49. Irizarry, RA, Hobbs, B, Collin, F, Beazer-Barclay, YD, Antonellis, KJ, Scherf, U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
50. Smyth, GK (2005). limma: Linear Models for Microarray Data. In: Gentleman, R, Carey, V, Dudoit, R, Irizarry, RA and Huber, W (eds.) Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Chapter 23. Springer-Verlag: New York. pp. 397-420. .
51. Benjamini, Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
52. Kwiecien, JM, Blanco, M, Fox, JG, Delaney, KH and Fletch, AL (2000). Neuropathology of bouncer Long Evans, a novel dysmyelinated rat. Comp Med 50: 503-510.
53. McGray, AJ, Hallett, R, Bernard, D, Swift, SL, Zhu, Z, Teoderascu, F et al. (2014). Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther 22: 206-218.
54. Popa, N, Cedile, O, Pollet-Villard, X, Bagnis, C, Durbec, P and Boucraut, J (2011). RAE-1 is expressed in the adult subventricular zone and controls cell proliferation of neurospheres. Glia 59: 35-44.
55. Hansen, CH, Holm, TL, Krych, ?, Andresen, L, Nielsen, DS, Rune, I et al. (2013). Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells. Eur J Immunol 43: 447-457.